Jean de Dieu Iragena
Biographic Data
| ID | 9070841 |
|---|---|
| NAME | Jean de Dieu Iragena |
| GIVEN NAMES | Jean de Dieu |
| FAMILY NAME | Iragena |
| SIGNATURE | IRAGENA J D |
| AFFILIATIONS | Makerere University |
| ORCID | 0000-0002-5237-9775 |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Tuberculosis laboratory capacity building in the WHO African Region
Tuberculosis remains a leading infectious disease killer in the World Health Organization African Region, with 2.5 million cases and 404,000 deaths in 2023, including 112,000 people with HIV. There is slow progress with only 42% of the 75% targeted reduction in death by 2025. Out of 60,266 estimated multidrug-resistant TB cases in 2023, only 22,515 were notified. Laboratory diagnostic services in the African region still need urgent attention. By…
Effectiveness of Xpert MTB/RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic
The Xpert MTB/RIF and Line Probe Assay (LPA) tests are more and more frequently used in mycobacteria testing laboratories for the rapid diagnosis of multi-drug resistance (MDR-TB). In this study, we demonstrate the effectiveness of these tests in the Central African Republic. Rifampicin resistance cases detected by the Xpert MTB/RIF during the year 2020 are also underwent first- and second-line LPA, and a first-line of drug susceptibility testing…
No prominent works on this page.
Effectiveness of Xpert MTB/RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic
The Xpert MTB/RIF and Line Probe Assay (LPA) tests are more and more frequently used in mycobacteria testing laboratories for the rapid diagnosis of multi-drug resistance (MDR-TB). In this study, we demonstrate the effectiveness of these tests in the Central African Republic. Rifampicin resistance cases detected by the Xpert MTB/RIF during the year 2020 are also underwent first- and second-line LPA, and a first-line of drug susceptibility testing…
Tuberculosis laboratory capacity building in the WHO African Region
Tuberculosis remains a leading infectious disease killer in the World Health Organization African Region, with 2.5 million cases and 404,000 deaths in 2023, including 112,000 people with HIV. There is slow progress with only 42% of the 75% targeted reduction in death by 2025. Out of 60,266 estimated multidrug-resistant TB cases in 2023, only 22,515 were notified. Laboratory diagnostic services in the African region still need urgent attention. By…
Tuberculosis (2 works) · Tuberculosis Research and Epidemiology (2 works) · Antibiotic Resistance in Bacteria (1 work) · Biology (1 work) · Capacity building (1 work) · Clinical Laboratory Practices and Quality Control (1 work) · Concordance (1 work) · Developing country (1 work) · Drug resistance (1 work) · First line (1 work)